Analyst firms · UBS · CHRS
UBS CHRS price target and rating history
Coherus Oncology Inc. (CHRS) · Health Care
UBS rates Coherus Oncology Inc. (CHRS) Neutral with a $1.50 price target, as of its latest action on Aug 16, 2024. It has published 3 rating actions on CHRS since June 2022, including 1 upgrade and 1 downgrade. Across 3 firms with a CHRS price target in the last 12 months, the median target is $10.
- Current rating
- Neutral
- Price target
- $1.50
- Median target, all firms
- $10
- Actions on CHRS
- 3
UBS price target on CHRS
Every UBS rating on CHRS
- Aug 16, 2024
- Mar 28, 2023
- Jun 14, 2022
How other firms rate CHRS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $7 | Oct 29, 2026 |
| Guggenheim | Buy | $12 | May 11, 2026 |
| Oppenheimer | Outperform | $10 | Jan 23, 2026 |
Questions about UBS and CHRS
- What is UBS's price target for CHRS?
- UBS's latest stated price target for Coherus Oncology Inc. (CHRS) is $1.50, from its action on Aug 16, 2024.
- What is UBS's rating on CHRS?
- UBS rates CHRS Neutral, a neutral rating, as of Aug 16, 2024.
- When did UBS last change its view on CHRS?
- On Aug 16, 2024, UBS downgrades to Neutral from Buy, price target $4 to $1.50.
- How does UBS's CHRS target compare with other analysts?
- Across 3 firms with a CHRS price target in the last 12 months, the median target is $10.
More CHRS rating histories
All UBS ratingsCHRS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.